Technology evaluation: HspE7, stressgen

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 3, 2005, Pages 256-263

  Maciag, Paulo Cesar ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEAT SHOCK PROTEIN 65; HYBRID PROTEIN; PEPTIDE; PLACEBO; R 1461; SGN 00101; VIRUS ANTIGEN; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONDYLOMA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOSTIMULATION; MYCOBACTERIUM BOVIS; NONHUMAN; PATENT; REVIEW; SIDE EFFECT; TOXICITY TESTING; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VIRUS INFECTION; WART VIRUS;

ANIMALS; BACTERIAL PROTEINS; CHAPERONINS; CLINICAL TRIALS, PHASE III; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS;

EID: 20344395103     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 271440 Stressgen moves new treatment for cervical cancer into development. Stressgen Biotechnology Corp PRESS RELEASE 1997 December 08
2. 296620 Stressgen reports second quarter results. Stressgen Biotechnology Corp PRESS RELEASE 1998 September 01
3. 313229 Streasgen initiates phase I clinical trial of HspE7 for cervical dysplasia. StressGen Biotechnologies Corp PRESS RELEASE 1999 February 02
4. 344720 Stressgen initiates phase II clinical trial of its lead compound HspE7; efficacy of HspE7 in high-grade anal dysplasia to be tested. StressGen Biotechnologies Corp PRESS RELEASE 1999 October 25
5. 360050 Stressgen Biotechnologies announces initiation of phase II study with HspE7. Stressgen Biotechnologies Corp PRESS RELEASE 2000 March 16
6. 367767 Stressgen reports fusion protein drug for human papillomavirus demonstrated positive immune responses and is well tolerated in phase I study - data presented at Annual Meeting of American Society of Clinical Oncology. Stressgen Biotechnotogles Corp PRESS RELEASE 2000 May 22
7. 368843 Antigen specific cell mediated immunity in phase I dose escalation trial of single doses of HspE-7 in healthy volunteers. Kadish AS, Wang Y, Ho G, He W, Chu NR, Winnet M, Talluri K, Mizzen L, Siegel I, Neefe JR PROC AM SOC CLIN ONCOL 2000 19 Abs 1789
8. 376324 Stressgen presents positive clinical data at 18th International Papillomavirus Conference: HspE7: A novel heat shock protein fusion for HPV-related diseases. Stressgen Biotechnologies Corp PRESS RELEASE 2000 July 26
9. 381859 Stressgen Biotechnologles initiates HspE7 phase II trial in cervical cancer. Stressgen Biotechnologies Corp PRESS RELEASE 2000 September 06
10. 388696 Stressgen initiates HspE7 phase III trial in HPV-related anal dysplasia; CDC reports HPV second only to HIV in US STD related healthcare costs. Stressgen Biotechnologies Corp PRESS RELEASE 2000 November 06
11. 389732 Stressgen reports third quarter financial results: Underwriters exercise their over-allotment option. Stressgen Biotechnologies Corp PRESS RELEASE 2000 November 14
12. 395633 Stressgen initiates phase II genital warts trial - trial expands broad-spectrum activity of HspE7 in HPV-related diseases. Stressgen Biotechnology Corp PRESS RELEASE 2001 January 09
13. 401365 Stressgen Biotechnologies announces 2000 financial results: Company demonstrated proof of principle with heat shock fusion technology and advanced lead product to phase III clinical trials. PRESS RELEASE 2001 March 08
14. 403082 Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) Hsp65 and HPV16 E7. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA CLIN EXP IMMUNOL 2000 121 2 216-225
15. 403517 Stressgen's HspE7 receives orphan drug status for recurrent respiratory papillomatosis. Stressgen Biotechnology Corp Press Release 2001 March 29
16. 405228 Stressgen's genital warts program ahead of schedule due to early completion of patient enrollment in phase II trial: First genital warts data to be presented in June 2001. Stressgen Biotechnologies Corp PRESS RELEASE 2001 April 10
17. 406969 Stressgen presents now data indicating the majority of anal dysplasia patients improve with HspE7: Data confirm earlier findings: 73% of patients downgrade from high grade to low grade dysplasia. StressGen Biotechnologies Corp PRESS RELEASE 2001 April 24
18. 407840 In vivo cytotoxic T-lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4+ T-cell independent. Huang Q, Richmond JF, Suzue K, Eisen HN, Young RA J EXP MED 2000 191 2 403-408
19. 408192 Hsp fusion technology- status of product development. Company World Wide Web site 2001 May 04
20. 411993 Preliminary clinical data demonstrate robust activity for HspE7 in genital warts. Stressgen Biotechnologies Corp PRESS RELEASE 2001 June 06
21. 417630 Stressgen completes early enrollment in its phase III trial for HspE7 for anal dysplasia caused by HPV. Stressgen Biotechnologies Corp PRESS RELEASE 2001 August 01
22. 421851 HspE7 treatment of anal dysplasia: Results of an open label trial of HspE7 and comparison with a prior controlled trial of low dose HspE7. Palefsky JM, Goldstone SE, Winnett M, Siegel MI, Neefe JR ICAAC 2001 41 Abs 1600
23. 429724 Stressgen initiates phase II recurrent respiratory papillomatosis trial in children. Stressgen Biotechnologies Corp PRESS RELEASE 2001 November 19
24. 431409 Stresagen announces robust HPV data from multiple phase II clinical trials. Stressgen Biotechnologies Corp PRESS RELEASE 2001 November 29
25. 434191 HspE7 potentially eliminates the need for surgical intervention and improves the quality of life in anal dysplasia patients 15-month data from ongoing registry indicate continued improvement to complete responses and durability. Stressgen Biotechnologies Corp PRESS RELEASE 2001 December 18
26. 434877 Stressgen announces issuance of US patent solidifying its heat shock protein-based technology platform. Stressgen Biotechnologies Corp PRESS RELEASE 2002 January 04
27. 437198 Stressgen's new European patent for heat shock protein fusions maximizes international marketing opportunities. Stressgen Blotechnologies Corp PRESS RELEASE 2002 January 23
28. 450579 Company reveals new aspects of mechanism of action for HspE7 and confirms immunostimulatory capabilities of platform technology for hepatitis B virus. Stressgen Biotechnologies Corp PRESS RELEASE 2002 May 07
29. 455972 Stressgen Biotechnologies and Roche announce global development and marketing collaboration valued up to $204 million US. PRESS RELEASE 2002 June 24
30. 455974 Roche's presence in virology strengthened through drug development collaboration with Victoria-based Stressgen. Stressgen Biotechnology Corp PRESS RELEASE 2002 June 24
31. 457276 Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC-101. Klencke B, Matijevic M, Urban RG, Lathey JL, Thatcher J, Weinberg V, Wilson J, Darragh T CLIN CANCER RES 2002 8 5 1028-1037
32. 466089 Stressgen announces presentation of data on the mechanism for the immunotherapeutic activity of HspE7 at HPV 2002. Stressgen Biotechnologies Corp PRESS RELEASE 2002 October 07
33. 466092 Stressgen announces presentation of new phase II HspE7 data on genital warts and anal dysplasia at HPV 2002. Stressgen Biotechnologies Corp PRESS RELEASE 2002 October 07
34. 476323 Stressgen announces the initiation of enrollment of patients for the first of multiple trials planned to evaluate HspE7 in HPV-related dysplasia and cancer. Stressgen Biotechnologies Corp PRESS RELEASE 2003 January 15
35. 477989 Stressgen granted European patent covering lead product HspE7 and other human papillomavirus therapeutics. StressGen Biotechnologies Corp PRESS RELEASE 2003 February 04
36. 480198 Stressgen granted US patent covering HspE7 and additional human papillomavirus therapeutic products. Stressgen Biotechnologies Corp PRESS RELEASE 2003 February 27
37. 487998 Stressgen receives Roche milestones totaling US$4.5 million. Stressgen Biotechnology Corp PRESS RELEASE 2003 April 30
38. 491189 Immunotherapy for HPV associated pre-cancer. Frazer IH, Leggatt GJ, Matsumoto K, De Kluyver R, Quinn M, Nicklin J, Tan J, Perrin L, O'Connor V, Ng, P, White O et al CANCER IMMUN 2003 3 Suppl 125
39. 492905 Stressgen announces statistically significant results with HspE7 to treat RRP. Stressgen Biotechnologies Corp PRESS RELEASE 2003 June 10
40. 499701 Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y J IMMUNOL 2001 167 11 6471-6479.
41. 501719 The causal relation between human papillomavirus and cervical cancer. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV J CLIN PATHOL 2002 55 4 244-265
42. 501720 Estimating the world cancer burden: Globocan 2000. Parkin DM, Bray F, Ferlay J, Pisani P INT J CANCER 2001 94 2 153-156
43. 501721 Roles of heat-shock proteins in innate and adaptive immunity. Srivastava P NAT REV IMMUNOL 2002 2 3 185-194
44. 501722 The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo. Harmala LA, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA J IMMUNOL 2002 169 10 5622-5629
45. 502168 Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Anthony LSD, Wu H, Sweet H, Turnnir C, Boux LJ, Mizzen LA VACCINE 1999 17 4 373-383
46. 502169 Activity of HspE7, a novel immunotherapy, in patients with anogenitall warts. Goldstone SE, Palefsky JM, Winnet MT, Neefe JR DIS COLON RECTUM 2002 45 4 502-507
47. 502171 Cervical and anal HPV infections in HIV positive women and men. de Sanjose S, Palefsky J VIRUS RES 2002 89 2 201-211
48. 502176 Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH et al VACCINE 2002 20 29-30 3456-3464
49. 503682 HspE7 treatment of pediatric recurrent respiratory papillomatosis (RRP): Interim results of an open-label trial. Derkay CS Arnold J Bower C McClay J Smith R van Burik J Wiatrak D Wohl BBerger D Neefe J ICAAC 2003 43 Abs G-1655
50. 504507 Papillomavirus vaccines in clinical trials. Galloway D LANCET INFECT DIS 2003 3 8 469-475
51. 504508 Cervical cancer vaccines: Progress and prospects. Steller MA J SOC GYNECOL INVEST 2002 9 5 254-264
52. 505082 Stressgen presents results of pediatric phase II RRP trial at ICAAC supporting pivotal phase III trial. Stressgen Biotechnologles Corp PRESS RELEASE 2003 September 16
53. 507427 List of all orphan products designations and approval. Federal Drug Agency INTERNET SITE 2002 October 15 (http://www.fda.gov)
54. 511305 Stressgen presents longer-term phase II data on HSPE7 for RRP at pediatric conference. Stressgen Biotechnologies Corp PRESS RELEASE 2003 November 03
55. 515802 Stressgen and Roche broaden heat shock protein agreement to maximize value of HspE7. PRESS RELEASE 2003 December 02
56. 516127 Stressgen receives FDA fast track designation for HspE7. PRESS RELEASE 2003 December 04
57. 524460 Stressgen reports HspE7 results from two clinical trials. PRESS RELEASE 2004 February 24
58. 525534 Stressgen Biotechnologies: Form 10-K 2003. FORM 10-K 2004 February 12
59. 561598 Stressgen granted additional patent covering use of lead compound, HspE7. Stressgen Biotechnologies Corp PRESS RELEASE 2004 September 29
60. 590711 Stressgen's HspE7 treatment showed higher than expected complete response rate among women with high grade cervical dysplasia. Stressgen Biotechnology Corp PRESS RELEASE 2005 March 21
61. 594967 Heat shock protein (Hsp)-based immunotherapy (HspE7) for treatment of CIN III (NCI 5850, NYGOG). SOCIETY OF GYNECOLOGIC ONCOLOGISTS ANNUAL MEETING 2005 March 21
62. 594969 Induction of CD4-independent CD8+ memory T cells by HspE7 fusion protein. INTERNATIONAL CONGESS ON IMMUNOLOGY 2004 July 22
63. 595013 Stressgen announces sale of bioreagents business for approximately CDN$8.0 million and withdraws preliminary prospectus for offering of common shares. Stressgen Biotechnology Corp PRESS RELEASE 2005 April 13
64. 595452 Memory CD8+ T cells induced by HspE7 fusion protein provide protection against tumor challenge. KEYSTONE SYMPOSIUM - BASIC ASPECTS OF TUMOR IMMUNOLOGY 2005 March 19-24
65. 599455 HspE7 treatment of pediatric recurrent respiratory papillomatosis (RRP): Interim results utilizing a laryngeal staging and severity scale (LSSS). Derkay CS, Arnold J, Bower C, McClay J, Smith R, Van Burik J, Wiatrak B, Wohl D, Berger B, Neefe J SOC EAR, NOSE THROAT ADV CHILD ANN MEET 2003 Oral presentation